| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680636 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2016 | 11 Pages |
Abstract
Amyloid is the principal target of late-stage development programs. There are relatively few agents in clinical trials for AD suggesting a need to amplify the drug discovery ecosystem.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Jeffrey Cummings, Travis Morstorf, Garam Lee,